" when the designation is granted?"
I'll go buy a beer for the leprechaun on the winged pegasus....
"low life scammer "
I assume once this pile of turd crashes you'll be saying "guy I should listened to......"
"With three blockbuster drugs lined up for quick FDA approvals (much less than one year)", can't even make that up
"Breakthrough Therapy or Accelerated Approval designation. The FDA will rule on AMPE's application by sometime in January."
Really? Where did you get this from? I assume you'll apologize for being wrong when January is done and no announcement of either?
Almost as funny as Rich Cavalli claiming in June 2012 "With three blockbuster drugs lined up for quick FDA approvals (much less than one year)"
3 drugs by June 2013, fantastic!
You guys are funny.
What "good news" are you talking about?
In AMPE's Oct. 2012 they were claiming they would start 3 phase 3 studies for scampion in Q4 12, and now they're starting a second study in Q1 14.....bit of a slip.
Also, zertane now seems to be off their list of assets. Wonder why? Didn;t the brilliant rich cavalli say it would be partnered soon...six months ago?
Still love this gem from Rich's July 2012 SA piece "With three blockbuster drugs lined up for quick FDA approvals (much less than one year)"
Yup, much less than one year!
In Q1, where AMPE will disclose a "positive" result without giving all the data, just like every other release of data. And, again, the brilliant Rich Cavalli's of the world will proclaim how great these half truths are, and the stock will rise until people realize the company is not giving all the data.....
This stock is a shorter's dream, thanks for the pop to 8+ Monday, 15% in 3 days is OK by me!
And, don't forget that typically (i.e. last 3 times AMPE has disclosed meetings with the FDA) it has done so the day after the meeting. That must mean this time it's really good news!
But AMPE does deceive and mislead, for example, by not disclosing full data in the ampion study: how many patients completed? What were baseline scores? What were scores for saline group? Real companies include these data in press releases, and don;t claim to be saving them for an academic presentation.
Here's another example of ampe deception, on optina. In its Feb. 2012 investor presentation it said the endpoints of the study were "Endpoints: Optical Coherence Tomography (OCT) and Visual Acuity using validated method". In its 8/1/12 PR it says "The primary endpoint was change from baseline to week twelve of treatment in retinal thickness as measured by Optical Coherence Tomography (OCT). Secondary endpoints were 1) change from baseline to week twelve in retinal volume and 2) change from baseline to week twelve in Early Treatment. "
Notice the difference? Deliberately left off the most important measure. Note, not disclosing viscual acuity data from the shortened phase 2 study could also be construed as misleading: they collected the data, why not disclose it? Any one? Rich?
How are those "two concurrent Phase III pivotal trials set to begin enrollment in 1Q13" for Zertane going? AMPE claimed this is Nov. 2012. How is that not deception, or did the studies start?
AMPE says itself:
"The FDA has previously indicated that a Phase III trial may be necessary following the current trial. "
Can you name 1 DME drug that was approved on a single 12 week study? Good luck!
As the brilliant richad cavlli wrote in a mya 2012 SA article ", it is reasonable to conclude that the path to approval by the FDA for Zertane will be relatively straightforward." So it must be close to approval!
and "The company has announced that it has already secured license agreements with two major pharmaceutical companies for the distribution of Zertane, and is in negotiations with several others. It is reasonable to assume that upon approval of Zertane by the FDA that the value of and demand for those license agreements will appreciate dramatically."
that was a year and a half ago, so Zertane must be doing well for scampio! good old rich, boy is he smart!
"the market cap is absurdly low for a Biotech with a likely blockbuster drug going commercial in late 2014 or 2015"
Yes, but the market cap is absurdly high for a total scam such as this that has no hope of ever getting anything approved. These guys can't even disclose complete results of a clinical study.
Actually, you get invited to investment bank conferences in banks think they can get fees from you for future secondaries, just like when this scam presented at the UBS conference.....
And let's not forget zertane! As the brillinat Richard Cavalli wrote on SA in June 2012 "There is no way to be certain but this sounds pretty much like negotiations have been underway with a licensing partner and now that critical clinical trial guidance details are known, a formal agreement can be formalized which means a big announcement may be coming soon!"
Coming soon! If it was coming soon 17 months ago, since how soon it must be coming now!
Certainly, the update in the 10-Q was super!
Interesting. So you're blaming management for not being able to fool smart institutional investors into buying what;s clearly a sham? AMPE is doing the best they can, with selective disclosure of data and grand promises that aren't met.
Maybe you should call AMPE and complain?
Thanks, I did manage to triple up above 10, so that was very helpful.
I agree AMPE has did a great job on the recent financing, and certainly am looking forward to seeing what big name funds bought in the deal (odd that no one has filed a form 13 yet....).
I'm pretty sure I chose the right company to short, but thanks for the concern.
So obvious market manipulators drivig the share price down!
As the brilliant Richard Cavalli wrote on about Ampion on SA in May 2012 "Ampio expects to complete its three-month, 1,500 patient trial this year and be ready for submission to the FDA for final approval. That's incredibly fast and the cost to inject 1,500 patients over three months will be incredibly small."
Wow, they must have filed for approval last year, and be close to marketing! Impressive!
Even better, as the genius Richard Cavalli wrote in June 2012 "With three blockbuster drugs lined up for quick FDA approvals (much less than one year)"
That's right folks, AMPIO got three blockbuster drugs approved in June 2013. Amazing!
How this isn't a $5,000 stock I don't know.
Last 3 times scampio met with the FDA they issued a PR the day after.....
Look up PRs from 8/1/12, 6/21/12, 5/11/12.....
Maybe they're too busy signing that partnership for Zertane
Thanks for buying those shares in the 10s!
But in selective disclosure of data AMPE is not being honest.
They did do a great job raising 25 mill, but this is still a sham. Not sure when it will implode, but i'll be shorting it!